← All drugs Report issue

jnj-80948543

mAbexperimental

Clinical trial activity

3 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

3

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Aug 18, 2022 (NCT05424822)

Timeline

No events for the selected filters.

Indications

Studied for

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainACTIVATOR
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
B-cell antigen receptor complex-associated protein beta chainBINDING AGENT
CD79B binding agent
- B-cell antigen receptor complex-associated protein beta chain (CD79B) ↗
B-lymphocyte antigen CD20BINDING AGENT
MS4A1 binding agent
- B-lymphocyte antigen CD20 (MS4A1) ↗

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06660563	Phase 1	Nov 5, 2024	—
NCT06139406	Phase 1	Dec 6, 2023	—
NCT05424822	Phase 1	Aug 18, 2022	—

Showing 3 of 3 trials

Page 1 / 1